scholarly journals Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States

Cancer ◽  
2015 ◽  
Vol 121 (15) ◽  
pp. 2544-2552 ◽  
Author(s):  
Sarah S. Mougalian ◽  
Pamela R. Soulos ◽  
Brigid K. Killelea ◽  
Donald R. Lannin ◽  
Maysa M. Abu-Khalaf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Neoadjuvant Chemotherapy ◽  
The United States ◽  
Stage I

scholarly journals Survival Differences in Chinese Versus White Women With Breast Cancer in the United States: A SEER-Based Analysis

2020 ◽  
pp. 1582-1592
Author(s):  
David W. Lim ◽  
Vasily Giannakeas ◽  
Steven A. Narod
Keyword(s):  
Breast Cancer ◽  
United States ◽  
White Women ◽  
Chinese Women ◽  
The United States ◽  
Stage I ◽  
Lymph Node Status ◽  
Breast Cancer Specific Survival ◽  
Cancer Specific Survival ◽  
Matched Design

PURPOSE The affect of race on breast cancer prognosis is not well understood. We compared crude and adjusted breast cancer survival rates of Chinese women versus White women in the United States. METHODS We conducted a cohort study of Chinese and White women with breast cancer diagnosed between 2004 to 2015 in the SEER 18 registries database. We abstracted information on age at diagnosis, tumor size, grade, lymph node status, receptor status, surgical treatment, receipt of radiotherapy and chemotherapy, and death. We compared crude breast cancer–specific mortality between the two ethnic groups. We calculated adjusted hazard ratios (HRs) in a propensity-matched design using the Cox proportional hazards model. P < .05 was considered statistically significant. RESULTS There were 7,553 Chinese women (1.8%) and 414,618 White women (98.2%) with stage I-IV breast cancer in the SEER database. There were small differences in demographics, nodal burden, and clinical stage between Chinese and White women. Ten-year breast cancer–specific survival was 88.8% for Chinese women and 85.6% for White women (HR, 0.73; 95% CI, 0.67 to 0.80; P < .0001). In a propensity-matched analysis among women with stage I–IIIC breast cancer, the HR was 0.71 (95% CI, 0.62 to 0.81; P < .0001). Annual mortality rates in White women exceeded those in Chinese women for the first 9 years after diagnosis. CONCLUSION Chinese women in the United States have superior breast cancer–specific survival compared with White women. The reason for the observed difference is not clear. Differences in demographic and tumor features between Chinese and White women with breast cancer may contribute to the disparity, as may the possibility of intrinsic biologic differences.

scholarly journals Breast Cancer by Age at Diagnosis in the Gharbiah, Egypt, Population-Based Registry Compared to the United States Surveillance, Epidemiology, and End Results Program, 2004–2008

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Jennifer A. Schlichting ◽  
Amr S. Soliman ◽  
Catherine Schairer ◽  
Joe B. Harford ◽  
Ahmed Hablas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Early Detection ◽  
Stage Iv ◽  
Tumor Grade ◽  
The United States ◽  
Stage I ◽  
Future Research ◽  
Breast Cancers ◽  
End Results

Objective. Although breast cancers (BCs) in young women often display more aggressive features, younger women are generally not screened for early detection. It is important to understand the characteristics of young onset breast cancer to increase awareness in this population. This analysis includes all ages, with emphasis placed on younger onset BC in Egypt as compared to the United States.Methods. BC cases in the Gharbiah cancer registry (GCR), Egypt, were compared to those in the Surveillance, Epidemiology, and End Results (SEER) database. This analysis included 3,819 cases from the GCR and 273,019 from SEER diagnosed 2004–2008.Results. GCR cases were diagnosed at later stages, with <5% diagnosed at Stage I and 12% diagnosed at Stage IV. 48% of all SEER cases were diagnosed at Stage I, dropping to 30% among those ≤40. Significant differences in age, tumor grade, hormone receptor status, histology, and stage exist between GCR and SEER BCs. After adjustment, GCR cases were nearly 45 times more likely to be diagnosed at stage III and 16 times more likely to be diagnosed at stage IV than SEER cases.Conclusions. Future research should examine ways to increase literacy about early detection and prompt therapy in young cases.

scholarly journals Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database

2020 ◽  
Vol 14 ◽  
pp. 117822342094569
Author(s):  
Zeina A Nahleh ◽  
Elizabeth B Elimimian ◽  
Leah C Elson ◽  
Brian Hobbs ◽  
Wei Wei ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Endocrine Therapy ◽  
Systemic Therapy ◽  
The United States ◽  
Stage I ◽  
Adjuvant Systemic Therapy ◽  
National Cancer Database ◽  
Her2 Positive ◽  
Positive Breast Cancer

Background: Guidelines regarding the usage of adjuvant systemic therapy in patients with small human epidermal growth factor receptor 2 (HER2)-positive and estrogen receptor/progesterone receptor–positive (luminal HER2 positive) tumors are nonspecific. Outcomes of chemotherapy followed by endocrine therapy (ET), with or without anti-HER2 therapy, vs ET alone (no chemotherapy) have not been widely studied in this disease subtype. We sought to examine the usage and outcomes of adjuvant systemic therapy (ET vs chemotherapy with or without trastuzumab) in stage I luminal HER2-positive breast cancer (BC), based on the large National Cancer Database. Methods: We conducted a retrospective analysis of patients with luminal HER2-positive stage I BC, diagnosed between 2010 and 2015, in the United States, using univariable and multivariable logistic regression analyses. The Kaplan-Meier method estimated overall survival (OS). Results: A total of 37 777 patients were included in the analysis; of these, n = 32 594 (86%) received adjuvant ET and n = 5183 (14%) received chemotherapy. Around 40% of all patients received anti-HER2 therapy (trastuzumab). Patients who received trastuzumab had a better 5-year OS (93.4% vs 92.0%, P = .0002) compared with those who did not. Patients who received anti-HER2 therapy plus ET had the best OS rate at 5 years (93.5%, confidence interval [CI]: 89.2%-98%, P < .0001) compared with those receiving anti-HER2 therapy plus chemotherapy (92.7%, CI: 89.4%-96.1%, P < .0001). Conclusions: Most patients in the United States, with stage I luminal HER2 positive BC, received ET, not chemotherapy but most of them do not receive anti-HER2 therapy resulting in inferior outcome. Future trials exploring the de-escalation of systemic adjuvant therapy for early-stage luminal HER2-positive BC to ET plus anti-HER2 therapy would be desirable.

scholarly journals Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: A report from the Breast Cancer Surveillance Consortium

Cancer ◽  
2015 ◽  
Vol 121 (9) ◽  
pp. 1369-1378 ◽  
Author(s):  
Kimberly H. Allison ◽  
Linn A. Abraham ◽  
Donald L. Weaver ◽  
Anna N. A. Tosteson ◽  
Heidi D. Nelson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Breast Biopsy ◽  
The United States ◽  
Cancer Surveillance ◽  
Breast Cancer Surveillance Consortium

scholarly journals Women's considerations and experiences for breast cancer screening and surveillance during the COVID-19 pandemic in the United States: A focus group study

2021 ◽  
Vol 151 ◽  
pp. 106542
Author(s):  
Karen E. Schifferdecker ◽  
Danielle Vaclavik ◽  
Karen J. Wernli ◽  
Diana S.M. Buist ◽  
Karla Kerlikowske ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Screening ◽  
Focus Group ◽  
Breast Cancer Screening ◽  
The United States ◽  
Focus Group Study ◽  
Screening And Surveillance

scholarly journals Anxiety- and Health-Related Quality of Life Among Patients With Breast Cancer: A Cross-Cultural Comparison of China and the United States

2018 ◽  
pp. 1-9
Author(s):  
Jin You ◽  
Qian Lu ◽  
Michael J. Zvolensky ◽  
Zhiqiang Meng ◽  
Kay Garcia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
United States ◽  
Trait Anxiety ◽  
State Anxiety ◽  
Cultural Context ◽  
The United States ◽  
Cross Cultural ◽  
Chinese Patients

Purpose Literature has documented the prevalence of anxiety and its adverse effect on quality of life among patients with breast cancer from Western countries, yet cross-cultural examinations with non-Western patients are rare. This cross-cultural study investigated differences in anxiety and its association with quality of life between US and Chinese patients with breast cancer. Methods Patients with breast cancer from the United States and China completed measures for anxiety (Spielberger State-Trait Anxiety Inventory) and quality of life (Functional Assessment of Cancer Therapy-Breast). Results After controlling for demographic and medical characteristics, Chinese patients reported higher levels of trait and state anxiety than US patients. Although there was an association between anxiety and quality of life in both groups of patients, the association between state anxiety and quality of life was stronger among Chinese patients than among US patients, with the association between trait anxiety and quality of life the same between the two cultural samples. Conclusion These findings suggest that anxiety and its association with quality of life among patients with breast cancer varies depending on cultural context, which reveals greater anxiety and poorer quality of life among Chinese patients compared with US patients. This suggests greater unmet psychosocial needs among Chinese patients and highlights the need to build comprehensive cancer care systems for a better quality of life in Chinese populations.

Sign in / Sign up

Export Citation Format

Share Document